Replies to post #240804 on Amarin Corp Plc (AMRN)

[Biobillionair]

I would say that's Shameless Pumping 101.

I would say you have no understanding of AMARIN IP or current case. Current case does not argue composition patents because there is no argument ... the generics would directly infringe on Vascepa composition patents...see stipulated facts. The composition patents are enough to bar launch of Vascepa composition in any indication.

Pumping is stretching truth beyond actual boarders... 10-4 patent stops composition similar to Vascepa according to claims, that’s call the law.

BB